相似文献
1
The modification of serum lipids after acute coronary syndrome and importance in clinical practice.
Curr Cardiol Rev. 2011 Nov;7(4):272-6. doi: 10.2174/157340311799960690.
2
Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Pharmacotherapy. 1995 May-Jun;15(3):317-37.
3
Changes in the concentration and composition of plasma lipoproteins during the acute phase response.
Curr Opin Clin Nutr Metab Care. 2002 Mar;5(2):153-8. doi: 10.1097/00075197-200203000-00006.
4
The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22.
Clin Cardiol. 2018 Jan;41(1):68-73. doi: 10.1002/clc.22851. Epub 2017 Dec 28.
5
Hyperlipidemia in childhood nephrotic syndrome.
Pediatr Nephrol. 1993 Oct;7(5):559-66. doi: 10.1007/BF00852550.
6
Analysis of lipoprotein-specific lipids in patients with acute coronary syndrome by asymmetrical flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Nov 1;1099:56-63. doi: 10.1016/j.jchromb.2018.09.016. Epub 2018 Sep 14.
7
Dyslipidemias and the secondary prevention of coronary heart disease.
Dis Mon. 1994 Aug;40(8):369-464. doi: 10.1016/0011-5029(94)90027-2.
8
Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass.
J Am Coll Surg. 2006 Jul;203(1):24-9. doi: 10.1016/j.jamcollsurg.2006.03.019. Epub 2006 May 30.
9
10
On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
Atherosclerosis. 1985 Jan;54(1):75-88. doi: 10.1016/0021-9150(85)90155-8.
引用本文的文献
1
Prevalence of Severe Hypercholesterolemia and Familial Hypercholesterolemia Phenotype in Patients with Acute Coronary Syndrome.
Medicina (Kaunas). 2025 Apr 7;61(4):681. doi: 10.3390/medicina61040681.
2
Lipid control and stroke risk in atrial fibrillation patients treated with direct oral anticoagulants and statins.
Eur Stroke J. 2025 Mar;10(1):137-144. doi: 10.1177/23969873241272530. Epub 2024 Aug 19.
3
Short-Course High-Intensity Statin Treatment during Admission for Myocardial Infarction and LDL-Cholesterol Reduction-Impact on Tailored Lipid-Lowering Therapy at Discharge.
J Clin Med. 2023 Dec 25;13(1):127. doi: 10.3390/jcm13010127.
4
Discordance analysis for apolipoprotein and lipid measures for predicting myocardial infarction in statin-treated patients with coronary artery disease: a cohort study.
J Geriatr Cardiol. 2023 Dec 28;20(12):845-854. doi: 10.26599/1671-5411.2023.12.001.
5
Genetic variants, gene expression, and soluble CD36 analysis in acute coronary syndrome: Differential protein concentration between ST-segment elevation myocardial infarction and unstable angina.
J Clin Lab Anal. 2022 Jul;36(7):e24529. doi: 10.1002/jcla.24529. Epub 2022 Jun 6.
6
PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction.
Life (Basel). 2022 Jan 27;12(2):190. doi: 10.3390/life12020190.
7
Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis.
Virol J. 2021 Jul 27;18(1):157. doi: 10.1186/s12985-021-01604-1.
8
Two Splice Variants (Long and Short) Are Differentially Expressed in Patients with Stable and Unstable Coronary Artery Disease: A Pilot Study.
Genes (Basel). 2021 Jun 19;12(6):939. doi: 10.3390/genes12060939.
9
Is Lipoprotein (a) a Risk Factor for Coronary Artery Ectasia?
Cardiol Res. 2020 Feb;11(1):50-55. doi: 10.14740/cr992. Epub 2020 Jan 26.
10
Lipid Profile of Patients with Acute Myocardial Infarction (AMI).
Cureus. 2019 Mar 18;11(3):e4265. doi: 10.7759/cureus.4265.
本文引用的文献
1
Serum lipid profile in patients with acute myocardial infarction.
Indian J Clin Biochem. 2004 Jan;19(1):67-70. doi: 10.1007/BF02872393.
2
The acute phase response inhibits reverse cholesterol transport.
J Lipid Res. 2010 Apr;51(4):682-4. doi: 10.1194/jlr.E005454. Epub 2010 Jan 13.
3
HDL as a biomarker, potential therapeutic target, and therapy.
Diabetes. 2009 Dec;58(12):2711-7. doi: 10.2337/db09-0538.
4
HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis.
Atherosclerosis. 2010 Jan;208(1):3-9. doi: 10.1016/j.atherosclerosis.2009.05.034. Epub 2009 Jun 6.
5
The HDL proteome: a marker--and perhaps mediator--of coronary artery disease.
J Lipid Res. 2009 Apr;50 Suppl(Suppl):S167-71. doi: 10.1194/jlr.R800097-JLR200. Epub 2008 Dec 5.
6
Lipid binding domains: more than simple lipid effectors.
J Lipid Res. 2009 Apr;50 Suppl(Suppl):S299-304. doi: 10.1194/jlr.R800078-JLR200. Epub 2008 Nov 13.
7
HDL remodeling during the acute phase response.
Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):261-7. doi: 10.1161/ATVBAHA.108.178681. Epub 2008 Nov 13.
8
Molecular structure of low density lipoprotein: current status and future challenges.
Eur Biophys J. 2009 Feb;38(2):145-58. doi: 10.1007/s00249-008-0368-y. Epub 2008 Sep 17.
9
Lipid levels in the post-acute coronary syndrome setting: destabilizing another myth?
J Am Coll Cardiol. 2008 Apr 15;51(15):1446-7. doi: 10.1016/j.jacc.2007.12.039.
10
Lipid levels after acute coronary syndromes.
J Am Coll Cardiol. 2008 Apr 15;51(15):1440-5. doi: 10.1016/j.jacc.2007.11.075.
Zotero 插件